# A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

Source: https://onco.cc/trials/nct05377996/  
OnCo record `nct05377996` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Emi-Le in triple-negative breast cancer, endometrial cancer, ovarian cancer and salivary gland cancers, run by Day One Biopharmaceuticals, Inc., now recruiting.

## Summary

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors is a phase 1/2 interventional study registered as NCT05377996 by Day One Biopharmaceuticals, Inc., with 360 participants planned, started 2022-08-15 and due to reach its primary completion in 2027-02. Interventions recorded: Emi-Le.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05377996
- Phase: 1/2
- Setting: A Phase 1/2, First-in-human, Multicenter Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Sponsor: Day One Biopharmaceuticals, Inc.
- Enrolled: 360

## Sources

- ClinicalTrials.gov NCT05377996: https://clinicaltrials.gov/study/NCT05377996

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Salivary gland cancers](https://onco.cc/cancers/salivary-gland/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- companies: [Day One Biopharmaceuticals](https://onco.cc/companies/day-one-biopharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct05377996.json